Purine and pyrimidine metabolism: still more to learn

Mammalian metabolism is heavily dependent on proper functioning of purine and pyrimidine synthesis, interconversion and degradation. Purine- and pyrimidine derived compounds are essential in numerous processes throughout life, including the synthesis of macromolecules, oxidative phosphorylation, signal transduction and high energy transfer. This ubiquitous presence is the reason that disturbances in purine and pyrimidine metabolism can result in life threatening clinical conditions. Understanding of this metabolism under normal and compromised circumstances is essential to diagnose inborn errors of purine and pyrimidine metabolism. The desire to gain more insight in these pathways is the basis of on going research covering different aspects of purine and pyrimidine metabolism, with special emphasis on purine biosynthesis, mitochondrial purine and pyrimidine metabolism and the pharmacogenetic aspects of synthetic purine and pyrimidine compounds. Other areas of interest are the role of the enzyme ITPase in mammalian metabolism and the development of diagnostic tools to detect defects in purine and pyrimidine metabolism on the metabolite, protein and molecular level. Inherited defects in purine and pyrimidine metabolism

[1]  J. Bierau,et al.  An HPLC-Based Assay of Adenylosuccinate Lyase in Erythrocytes , 2011, Nucleosides, nucleotides & nucleic acids.

[2]  A. Paulussen,et al.  The Effect of ITPA Polymorphisms on the Enzyme Kinetic Properties of Human Erythrocyte Inosine Triphosphatase Toward its Substrates ITP and 6-Thio-ITP , 2011, Nucleosides, nucleotides & nucleic acids.

[3]  J. Bierau,et al.  A role for ITPA variants in the clinical course of pulmonary Langerhans' cell histiocytosis? , 2010, European Respiratory Journal.

[4]  L. Zoetekouw,et al.  Dihydropyrimidine Dehydrogenase Deficiency Caused by a Novel Genomic Deletion c.505_513del of DPYD , 2010, Nucleosides, nucleotides & nucleic acids.

[5]  Jacques Fellay,et al.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C , 2010, Nature.

[6]  J. Bierau,et al.  Biochemical abnormalities in a patient with thymidine phosphorylase deficiency with fatal outcome , 2010, Journal of Inherited Metabolic Disease.

[7]  J. Bakker,et al.  Azathioprine induced pneumonitis in a patient with ulcerative colitis. , 2009, Journal of Crohn's & colitis.

[8]  H. Smeets,et al.  The unfolding clinical spectrum of POLG mutations , 2009, Journal of Medical Genetics.

[9]  B. Ylstra,et al.  Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3) , 2009, Human Genetics.

[10]  J. Bierau,et al.  Therapeutic regimens in interstitial lung disease guided by genetic screening: fact or fiction? , 2007, European Respiratory Journal.

[11]  J. Bierau,et al.  Pharmacogenetic significance of inosine triphosphatase. , 2007, Pharmacogenomics.

[12]  D. Hommes,et al.  Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[13]  J. Bierau,et al.  The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients , 2005, Alimentary pharmacology & therapeutics.

[14]  W. Nyhan.  Disorders of purine and pyrimidine metabolism. , 2005, Molecular genetics and metabolism.

[15]  B. Flourié,et al.  Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE). , 2005, Gastroenterologie clinique et biologique.

[16]  M. Baumgartner,et al.  Inborn Metabolic Diseases , 1995, Springer Berlin Heidelberg.